At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Trading 05-21 09:45:06 EDT
421.01
-5.90
-1.38%
High423.30Low414.38Vol1.03M
Open423.30D1 Closing426.92Amplitude2.09%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O22.33MT/O Rate--Tradable Shares0.00
P/B2.530263ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity
TIPRANKS  ·  19:16
Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity
Beam Therapeutics presents Phase 1/2 data for BEAM-302
TIPRANKS  ·  05-19 04:35
Beam Therapeutics presents Phase 1/2 data for BEAM-302
Beam Therapeutics presents Phase 1/2 BEAM-302 AATD trial data at ATS 2026
Reuters  ·  05-19 04:00
Beam Therapeutics presents Phase 1/2 BEAM-302 AATD trial data at ATS 2026
Sangamo publishes corporate presentation on neurology genomic medicine platform, Fabry gene therapy
Reuters  ·  05-15
Sangamo publishes corporate presentation on neurology genomic medicine platform, Fabry gene therapy
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)
Simply Wall St.  ·  05-15
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)
Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study
MT Newswires Live  ·  05-14
Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study
Editas Medicine Reports New Preclinical Data Demonstrating Progress of Edit-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
THOMSON REUTERS  ·  05-14
Editas Medicine Reports New Preclinical Data Demonstrating Progress of Edit-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)
TIPRANKS  ·  05-14
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Caris Life Sciences, Inc. (CAI)
Cathie Wood's Flagship Fund Is Largely Missing Out on a Booming Tech-Fueled Bull Run
Dow Jones  ·  05-14
Cathie Wood's Flagship Fund Is Largely Missing Out on a Booming Tech-Fueled Bull Run
Intellia Therapeutics Is Maintained at Market Perform by Bernstein
Dow Jones  ·  05-14
Intellia Therapeutics Is Maintained at Market Perform by Bernstein
High Growth Tech Stocks In The US For May 2026
Simply Wall St.  ·  05-13
High Growth Tech Stocks In The US For May 2026
Intellia Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $25 From $30
THOMSON REUTERS  ·  05-13
Intellia Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $25 From $30
Analysts Conflicted on These Healthcare Names: Omnicell (OMCL), Beam Therapeutics (BEAM) and Zentalis Pharmaceuticals (ZNTL)
TIPRANKS  ·  05-13
Analysts Conflicted on These Healthcare Names: Omnicell (OMCL), Beam Therapeutics (BEAM) and Zentalis Pharmaceuticals (ZNTL)
Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline
Simply Wall St.  ·  05-13
Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline
Beam Therapeutics to present updated BEACON trial biomarker data for risto-cel in SCD at EHA2026
Reuters  ·  05-12
Beam Therapeutics to present updated BEACON trial biomarker data for risto-cel in SCD at EHA2026
Sangamo Therapeutics posts ST-503 nonclinical safety presentation for small fiber neuropathy
Reuters  ·  05-12
Sangamo Therapeutics posts ST-503 nonclinical safety presentation for small fiber neuropathy
Sangamo Therapeutics publishes ST-506 nonhuman primate brain presentation
Reuters  ·  05-12
Sangamo Therapeutics publishes ST-506 nonhuman primate brain presentation
Sangamo publishes TRAC locus modular integrase retargeting presentation
Reuters  ·  05-12
Sangamo publishes TRAC locus modular integrase retargeting presentation
A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest
Simply Wall St.  ·  05-12
A Look At CRISPR Therapeutics (CRSP) Valuation As CASGEVY Progress And New Funding Lift Investor Interest
Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran
TIPRANKS  ·  05-12
Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--